参考文献/References:
[1] 陈万青, 郑荣寿, 曾红梅, 等. 2011 年中国恶性肿瘤发病和死亡分析[J]. 中国肿瘤, 2012, 24(1): 1-10.
[2] 叶定伟. 前列腺癌的流行病学和中国的发病趋势 [J]. 中华外科杂志, 2006, 44(6): 362-364.
[3] 董隽. 激素难治性前列腺癌对多西他赛耐药机制的研究进展[J].中华泌尿外科学杂志, 2011, 32(2): 138-140.
[4] Lassi K, Dawson NA. Emerging the rapiesin castrate-resistant prostate cancer[J]. Curr Opin Oncol, 2009, 21(3): 260-265.
[5] Lam JS, Leppert JT, Vemulapalli SN, et al. Secondary hormonal therapy for advanced prostate cancer [J].Urol, 2006, 175(1): 27-34.
[6] 那彦群, 叶章群, 孙颖浩, 等. 2014 版中国泌尿外科疾病诊断治疗指南[M]. 人民卫生出版社, 2013, 80.
[7] Tannock IF,Osoba D, Stockler MR, et al. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points[J]. J Clin Oncol, 1996, 14(6): 1756-1764.
[8] Tannock IF, de Wit R, Berry W R, et al. Docetaxel plus predninseo or mitoxantrone plus prednisone for advanced prostate cancer[J]. N Engl J Med, 2004, 351 (15): 1502-1512．
[9] De Bono JS, Oudard S, Ozguroglu M, et a1. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial[J]. Lancet, 2010, 376(9747): 1147-1154.
[10] 陈彼得, 俞世成, 李恭会. 多西他赛治疗失败后的去势抵抗性前列腺癌及其骨转移治疗进展[J]. 浙江大学学报（医学版），2014,43(1): 115-118，封3.
[11] Omlin A, Pezaro C, Gillessen Sommer S. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy[J]. Ther Adv Urol, 2014, 6(1): 3-14.
[12] Attard G, Reid AH, A'Hern R, et al. Selective inhibition of CY1P7 with abiraterone acetate is highly active in the treatment ofa stcrationresistant prostate cancer[J]. J Clin Oncol, 2009, 27(23): 37423-748.
[13] De Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer[J]. N Engl J Med,2011, 364(21): 1995-2005.
[14] Tran C, Ouk S, Cleegg NJ, et al. Development of a second-generation antiandrogen for treatment of ad-vanced prostate cancer[J]. Sceince, 2009, 324(5928): 787-790.
[15] Ferlay J,Shin H R,Bray F, et al.Estimates of world-wide burden of cancer in 2008: GLOB-OCAN 2008[J].Int J Cancer, 2010, 127(12):2893-2917.
[16] Beer T M, Tombal B. Ezalutamide in metastatic pros-tate cancer before chemotherapy[J]. N Engl J Med, 2014, 371(18): 1755-1756.
[17] Kantoff PW, Higano CS, Shore ND, et al. Sipuleucel-T immunotherapy for Castration-Resistant prostate cancer[J]. N Engl J Med, 2010, 363(5): 411-422.
[18] Higano CS, Schellhammer PF, Small EJ, et al. Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer[J]. Cancer, 2009, 115(16): 3670-3679.
[19] Simondsen K, Kolesar J. New treatment options for castrationresistant prostate cancer[J]. Am J Health Syst Pharm, 2013, 70(10):856-865.
[20] 许标波, 贺毅憬, 王韦力, 等. 肿瘤免疫检查点抑制剂临床治疗的研究进展[J]. 中国临床药理学与治疗学, 2016, 21(2): 218-224.
[21] Kwon ED, Drake CG, Scher HI, et al. Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial[J]. Lancet Oncol, 2014, 15(7): 700-712.
[22] Lee RJ. Smith MR. Targeting MET and vascular endothelial growth factor receptor signaling in castration-resistant prostate canecr[J]. Cancer J, 2013, 19(1): 90-98.
[23] Lee RJ, Saylor PJ, Michaelson MD, et al. A dose-ranging study of cabozantinib in men with castration-resistant prostate cancer and bone metastases[J]. Clin Cancer Res, 2013, 19(11): 3088-3094.
[24] Smith DC, Smith MR, Sweeney C, et al. Cabozantinib in patients with advanced prostate cancer: results of a phase II randomized discontinuation trial[J]. J Clin Oncol, 2013, 31(4): 412-419.
[25] 田俊波, 董自强, 曾文, 等. 分子靶向治疗在前列腺癌中的研究进展[J]. 现代生物医学进展, 2015, 15(10): 1984-1986.
[26] Nilsson S, Franzén L, Parker C, et al. Bone-targeted radium-22 3in symptomatic, hormone-refractory prostate cancer: a randomised,multicentre, placebo-controlled phase II study[J]. Lancet Oncol,2007, 8(7): 587-594.
[27] 温耀安, 王沈凡, 宋先璐, 等. 二氯化镭223 治疗伴骨转移前列腺癌的药理及临床评价[J]. 中华泌尿外科学杂志, 2016,37(11):878-880.
[28] Cookson MS, Roth BJ, Dahm P, et al. Castration-resistant prostate cancer: AUA Guideline[J]. J Urol, 2013, 190(2):429-438.
[29] Coogan CL, McKiel CF. Percutaneous cryoablation of the prostate :preliminary results after 95 procedures [J]. J Urol, 1995, 154(5):1813-1817.
[30] 中华医学会泌尿外科学分会, 中国前列腺癌联盟. 转移性前列腺癌化疗中国专家共识(2017 版)[J]. 中华泌尿外科学杂志, 2017,38(3): 161-165.
[31] 陈征, 邵春奎, 高新. Gleason 评分研究进展及评估前列腺癌预后的重要性[J/CD]. 中华腔镜泌尿外科杂志( 电子版), 2016, 10(6):367-372.
[32] Lubaroff DM. Prostate cancer vaccines in clinical trials[J]. Expert Rev Vaccines, 2012, 11(7): 857-868．
相似文献/References:
[1]周建华,高新,蔡育彬,等.腹腔镜前列腺癌根治术126例3年随访结果[J].中华腔镜泌尿外科杂志(电子版),2007,(01):22.
ZHOU Jian-hua,GAO Xin,CAI Yu-bin,et al.Results of study of 126 cases underwent laparoscopic radical Prostatectomy during three years' follow-up[J].,2007,(01):22.
[2]关健强,周少丽,龚楚链,等.腹腔镜下前列腺癌根治术中呼气末CO2分压的变化及意义[J].中华腔镜泌尿外科杂志(电子版),2008,(03):37.
GUAN Jian-qiang,ZHOU Shao-li,GONG Chu-lian,et al.Difference between arterial and end-tidal carbon dioxide pressures in laparoscopic radical prostarectome[J].,2008,(01):37.
[3]乔鹏,邢念增.经腹膜外腹腔镜前列腺癌根治术(附9例报告)[J].中华腔镜泌尿外科杂志(电子版),2009,(01):25.
QIAO Peng,XING Nian-zeng.Extraperitoneal laparoscopic radical prostatectomy: a report of 9 cases[J].,2009,(01):25.
[4]进展,孙其鹏,高新.TMPRSS2-ETS融合基因在前列腺癌研究的进展[J].中华腔镜泌尿外科杂志(电子版),2009,(04):354.
[5]黄海,杜涛,黄健,等.高效抑制核因子κ-B的茎环RNA基因序列的获得[J].中华腔镜泌尿外科杂志(电子版),2009,(05):444.
[6]高新,邱剑光,周祥福,等.腹腔镜前列腺癌根治术5年随访结果——中国单中心170例报道[J].中华腔镜泌尿外科杂志(电子版),2010,(01):2.
GAO Xin,QIU Jian-guang,ZHOU Xiang-fu,et al.Laparoscopic radical prostatectomy:oncological and functional results of 170 patients with a minimum 5-year follow-up[J].,2010,(01):2.
[7]刘伟鹏,庞俊,李辽源,等.前列腺癌CRMP4基因启动子甲基化研究[J].中华腔镜泌尿外科杂志(电子版),2010,(01):57.
LIU Wei-peng,PANG Jun,LI Liao-yuan,et al.A study on promoter methylation of CRMP4 in prostate cancer[J].,2010,(01):57.
[8]孙其鹏,庞俊,李辽源,等.荧光原位杂交技术在前列腺癌诊断中的临床应用[J].中华腔镜泌尿外科杂志(电子版),2010,(01):64.
SUN Qi-peng,PANG Jun,LI Liao-yuan,et al.Detection of TMPRSS2-ETS fusions by a multiprobe fluorescence in situ hybridization assay for the diagnosis of prostate cancer[J].,2010,(01):64.
[9]蒲小勇,陆敏华,高新,等.不同穿刺针数经直肠前列腺穿刺活检诊断前列腺癌的研究[J].中华腔镜泌尿外科杂志(电子版),2010,(05):347.
PU Xiao-yong,LU Ming-hua,GAO Xin,et al.Comparative study of the different cores using transrectal prostate biopsy in diagnosis of prostate cancer[J].,2010,(01):347.
[10]刘小彭,高新,周祥福,等.耻骨后前列腺癌根治术联合内分泌治疗T3N1期前列腺癌[J].中华腔镜泌尿外科杂志(电子版),2010,(05):374.
LIU Xiao-peng,GAO Xin,ZHOU Xiang-fu,et al.Radical prostatectomy combining with adjuvant hormone therapy for treatment of prostate cancer with pelvic lymph node metastasis[J].,2010,(01):374.